🛰️ Daily AI Frontier
‹ back to 2026-09-17

Evolution and heterogeneity of lethal metastatic bladder cancer subtypes

Research Medical/Healthcare AI

Ranking

Overall 78
Content 90
Popularity 49

Observed public metrics from 1 member.

Merged summary

TL;DR - A Nature study uses a rapid autopsy programme to investigate the molecular and genetic evolution of lethal metastatic bladder cancer. The resource may clarify how aggressive histological subtypes become heterogeneous and develop treatment resistance.

  • Examines metastatic bladder cancer across its temporal evolution.
  • Focuses on aggressive histological subtypes and tumour heterogeneity.
  • Supports detailed molecular and genetic analyses of therapy resistance.
  • The provided abstract does not report specific methods or findings.

Sources (1)

Evolution and heterogeneity of lethal metastatic bladder cancer subtypes

Nature Pushpa Itagi, Samantha L. Schuster, Sonali Arora, Thomas W. Persse, Jennifer A. Waters, Michael Yang, Alan Min, Pooja Chandra, Mohamed Adil, Patricia C. Galipeau, Dmytro Rudoy, Allie S. Kreitman, Yixin Lin, Minjeong Ko, Erolcan Sayar, Robert D. Patton, Lori Kollath, Abby Meis, Samuel Lindergren, Nathan Ji, Khursheed Ali, Hrishi Venkatesh, Cynthia L. Wladyka, A. Patrick McDeed, Claire B. Mills, Manasvita Vashisth, Jin Yeong Kim, Rosa Nadal, Jessica E. Hawley, Todd A. Yezefski, Sarah P. Psutka, John L. Gore, Daniel W. Lin, Peter S. Nelson, Heather H. Cheng, Michael T. Schweizer, Lawrence Fong, John K. Lee, Evan Y. Yu, Eva Corey, Colm Morrissey, Petros Grivas, Robert B. Montgomery, Jonathan L. Wright, Michael C. Haffner, Funda Vakar-Lopez, Omar Y. Mian, Hung-Ming Lam, Andrew C. Hsieh, Gavin Ha 2026-09-16 doi:10.1038/s41586-026-11035-z
Public signals OpenAlex citations 0
Providers: Hugging Face · N/A OpenAlex · Citations 0 Publisher · N/A Semantic Scholar · N/A X · N/A Fetched 2026-09-25 14:18:47.014013 UTC

TL;DR - A Nature study uses a rapid autopsy programme to investigate the molecular and genetic evolution of lethal metastatic bladder cancer. The resource may clarify how aggressive histological subtypes become heterogeneous and develop treatment resistance.

  • Examines metastatic bladder cancer across its temporal evolution.
  • Focuses on aggressive histological subtypes and tumour heterogeneity.
  • Supports detailed molecular and genetic analyses of therapy resistance.
  • The provided abstract does not report specific methods or findings.
item →